Russia Insulin Drugs & Delivery Devices Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

Russia Insulin Drugs and Delivery Devices Market is segmented into Drugs (Basal or Long-acting Insulins, Bolus or Fast-acting Insulins, Traditional Human Insulins, Combination Insulins, and Biosimilar Insulins), Devices (Insulin Pens, Insulin Pumps, Insulin Syringes, and Jet Injectors). The report offers the value (in USD million) and volume (in million mL) for insulin drugs and (in unit million) for the devices for the above segments.

Russia Insulin Drugs & Delivery Devices Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

Russia Insulin Drugs & Delivery Devices Industry Overview

Russia Insulin Drugs and Delivery Devices Market is consolidated, with few significant and generic players. Mergers and acquisitions that happened between the players in the recent past have helped the companies strengthen their market presence. Eli Lilly and Boehringer Ingelheim together have an alliance in developing and commercializing Basaglar (Insulin Glargine). Additionally, the players in the recent past helped the companies strengthen their market presence; for example, Novo Nordisk collaborated with Ypsomed to provide better insulin therapy solutions.

Russia Insulin Drugs & Delivery Devices Market Leaders

  1. Roche

  2. Medtronics

  3. Novo Nordisk

  4. Eli Lilly

  5. Sanofi

  6. *Disclaimer: Major Players sorted in no particular order
RussiaDD.png

Russia Insulin Drugs & Delivery Devices Market Report Snapshots

80% of our clients seek made-to-order reports. How do you want us to tailor yours?